These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Ongoing||2014-001263-12||Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation (METROS) Crizotinib nel tumore pretrattato al polmone non a piccole cellule con amplifica...||not-yet-due|
|Ongoing||2016-001259-34||PF-06463922 for crizotinib pretreated ROS1 positive non-small-cell lung cancer: a phase II Trial (PFROST) PF-06463922 nel tumore al polmone non a piccole cellule con traslocazione ROS1 pretrattat...||not-yet-due|
|Ongoing||2016-004003-31||SQUINT (Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An open-label, randomized, phase II trial of Nivolumab plus Ipilimumab versus platinum-based chemotherapy in chemonaive metastatic or recurr...||not-yet-due|
|Ongoing||2017-003509-16||Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC) Livelli sierici di citochine come predittori di effic...||not-yet-due|
|Ongoing||2017-004157-16||Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Studio di fase II a singolo braccio con cabozantinib in pazienti con carcinoma polmonare non...||not-yet-due|
|Ongoing||2018-003645-41||Phase II trial evaluating the efficacy of durvalumab (MEDI4736) as second-line therapy in Non- Small-Cell Lung Cancer patients receiving concomitant steroids Studio di fase II che mira a valutare l...||not-yet-due|
|Ongoing||2018-003973-82||Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients Studio randomizzato di fase...||not-yet-due|
|Ongoing||2019-002869-35||A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer...||not-yet-due|
|Exempt||2019-004070-26||A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer and ...||not-yet-due|
|Ongoing||2020-005170-10||A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer progress...||not-yet-due|
|Completed, but no date Terminated||2020-005890-29||Comparative efficacy of therapeutic strategies for at home early treatment of mild or moderate COVID-19 patients on the reduction of the risk of disease worsening: A multi-stage multi-arm adaptive ran...||bad-data|
|Ongoing||2021-001713-37||Phase II, two-cohorts, randomized trial comparing standard of care versus immune-based combination in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durval...||not-yet-due|